Independent Data Monitoring Committee recommends continuing the trial evaluating temelimab in Long COVID without any modifications

Geneva, Switzerland, December 11th, 2023 – 8:00 AM CET – GeNeuro (Euronext Paris: CH0308403085 – GNRO), a biopharmaceutical company focused on stopping causal factors driving the progression of neurodegenerative and autoimmune diseases such as multiple sclerosis (MS), amyotrophic lateral sclerosis (ALS) and Post-Acute Sequelae of COVID-19 (PASC, Long-COVID or post-COVID), today announced that, as planned in […]

GeNeuro announces completion of recruitment of its long-COVID Phase 2 trial and confirms top-line results for June 2024

Geneva, Switzerland, November 28, 2023 – 8:00 AM CET – GeNeuro (Euronext Paris: CH0308403085 – GNRO), a biopharmaceutical company focused on stopping causal factors driving the progression of neurodegenerative and autoimmune diseases such as multiple sclerosis (MS), amyotrophic lateral sclerosis (ALS) and Post-Acute Sequelae of COVID-19 (PASC, long-COVID or post-COVID), today announced the completion of the […]

GeNeuro and Verily Collaborate to Advance Long-COVID Research

Geneva, Switzerland, October 19, 2023 – 8:00 AM CEST – GeNeuro (Euronext Paris: CH0308403085 – GNRO), a biopharmaceutical company developing novel treatments for neurodegenerative and autoimmune diseases, announced a collaboration with Verily, an Alphabet precision health technology company, to investigate biomarkers related to activation of the proinflammatory HERV-W envelope protein (W-ENV) in SARS-CoV-2 infection. https://geneuro.com/data/news/GeNeuro-PR-Verily-collaboration-19-10-2023-ENG.pdf

GeNeuro Reports 2023 Half-Year Results and Provides Corporate Update

Geneva, Switzerland, September 29, 2023, at 6:30pm CEST – GeNeuro (Euronext Paris: CH0308403085 – GNRO), a biopharmaceutical company focused on stopping causal factors driving the progression of neurodegenerative and autoimmune diseases such as multiple sclerosis (MS), amyotrophic lateral sclerosis (ALS) and Post-Acute Sequelae of COVID-19 (PASC, long-COVID or post-COVID), today reported its half-year financial results […]

New study published in PNAS further substantiates the neuropathogenic role of the HERV-W protein in MS 

Geneva, Switzerland, September 27, 2023 –7:30am CEST – GeNeuro (Euronext Paris: CH0308403085 – GNRO), a biopharmaceutical company developing treatments for neurodegenerative and autoimmune diseases, such as multiple sclerosis (MS), amyotrophic lateral sclerosis (ALS) and the severe neuro-psychiatric consequences of COVID-19 (post-COVID or Long-COVID), today announced, in collaboration with the Heinrich-Heine University in Düsseldorf, the publication in […]

Recent study demonstrates the strong link between SARS-CoV-2 infection and HERV-W activation in hospitalized psychotic patients

Geneva, Switzerland, September 11, 2023 – 7.30 AM CEST – GeNeuro (Euronext Paris: CH0308403085 – GNRO), a biopharmaceutical company developing treatments for neurodegenerative and autoimmune diseases, such as multiple sclerosis (MS), amyotrophic lateral sclerosis (ALS) and the severe neuro-cognitive consequences of COVID-19 (post-COVID or Long-COVID), today announced, in collaboration with Professor Marion Leboyer from the FondaMental […]

GeNeuro: financial information for the second quarter 2023

Geneva, Switzerland, July 25, 2023 – 6.00 pm CEST – GeNeuro (Euronext Paris: CH0308403085 – GNRO), a biopharmaceutical company developing treatments for neurodegenerative and autoimmune diseases, such as multiple sclerosis (MS), amyotrophic lateral sclerosis (ALS) and the severe neuropsychiatric consequences of COVID-19 (post-COVID or Long-COVID), today reported on its 2023 second quarter cash position. https://geneuro.ch/data/news/GeNeuro-PR-Q2-2023-EN.pdf

GeNeuro Announces Approval of all Resolutions Proposed at 2023 Annual General Meeting

Geneva, Switzerland, June 15, 2023 – 6:30pm CEST – GeNeuro (Euronext Paris: CH0308403085 – GNRO), a biopharmaceutical company developing treatments for neurodegenerative and autoimmune diseases, such as multiple sclerosis (MS), amyotrophic lateral sclerosis (ALS) and the severe neuropsychiatric consequences of COVID-19 (post-COVID or Long-COVID), today announced that its shareholders have approved all resolutions proposed at its […]

Availability of documents for AGM 2023

Geneva, Switzerland, May 24, 2023 – 6:00pm CEST – GeNeuro (Euronext Paris: CH0308403085 – GNRO), a biopharmaceutical company developing treatments for neurodegenerative and autoimmune diseases, such as multiple sclerosis (MS), amyotrophic lateral sclerosis (ALS) and the severe neuropsychiatric consequences of COVID-19 (post-COVID or Long-COVID), informs its shareholders that the 2023 Annual General Meeting will be held […]

New study published in Cell Press demonstrates that SARS-CoV-2 awakens ancient retroviral genes and the expression of proinflammatory HERV-W envelope protein in COVID-19 patients

Geneva, Switzerland, May 3, 2023 – 8:00am CEST – GeNeuro (Euronext Paris: CH0308403085 – GNRO), a biopharmaceutical company developing novel treatments for neurodegenerative and autoimmune diseases such as multiple sclerosis (MS), amyotrophic lateral sclerosis (ALS) and the severe consequences of COVID-19, (PASC, post-COVID or Long-COVID), announced today the publication in the leading open science journal iScience […]